Its system of action entails the selective blockade of multiple ion stations in the center that are regarded as energetic during episodes of atrial fibrillation. In 2003 October, Cardiome granted Astellas Pharma US, Inc. A special license to develop and commercialize KYNAPID in THE UNITED STATES, with Astellas responsible for 75 percent of development costs. Astellas and Cardiome carried out four successful Phase 3 scientific trials which demonstrated the potential for KYNAPID as a transformation agent. In 2004 and September 2005 December, we announced positive top-line results for the second and first pivotal Stage 3 atrial fibrillation trials, or Action 1 and ACT 3, respectively.The acquisition increases the total size of ARC Healthcare’s portfolio to approximately $164.5 million, comprising 12 properties. The one-story, 11,000 square feet building is 100 percent leased to The Cooper Wellness System, a fresh Jersey not-for-profit corporation. In April 2010 and includes a 10-year term expiring in April 2020 The lease commenced.. Agendia to participate in groundbreaking clinical trial for breast cancer Agendia, a worldwide world innovator in molecular tumor diagnostics, today it will participate in the highly anticipated I-SPY 2 TRIAL for breasts cancer announced, set to launch in the first of nearly twenty analysis sites.